Star Therapeutics Secures $125M to Advance VGA039 for Von Willebrand Disease

Star Therapeutics has raised $125 million to propel the development of VGA039, a subcutaneous monoclonal antibody targeting Protein S. This investigational therapy aims to restore blood clotting balance in individuals with all types of von Willebrand disease.

Source: National Bleeding Disorders Foundation, NBDF Notes, October 2025